Ibodutant

Ibodutant

Ibodutant is a candidate drug against irritable bowel syndrome, developed by The Menarini Group. As of May 2008, it is undergoing a multicentre double blind dose finding study.

Method of action

Ibodutant selectively blocks the tachykinin receptor NK2. Blockage is practically complete in nanomolar concentrations.

References